APOBEC and replication-associated mutagenesis contribute to the development of ETV6-RUNX1 ALL, creating massive leukemic population genetic diversity that results in clonal differences in susceptibilities to chemotherapy.
Introduction
Analogous to organismal evolution in an ecosystem, the environmental selection pressures, population size, and rate of genome modification are core determinants of tumor evolutionary dynamics 1 . Contemporary bulk sequencing methods that interrogate the ensemble-averaged mutational profiles of the genomes of thousands of cells predominantly identify those mutations present in the most dominant tumor subclones at diagnosis 2 . However, bulk sequencing strategies are limited in their ability to capture the full genetic diversity of a population, as they do not identify lower-frequency clones and variants. A deeper understanding of the genetic diversity within tumors is key to understanding tumor evolution, including that of malignant cell populations that may increase in size as the relative fitness of clones changes in response to new selection pressures as patients undergo treatment.
Our knowledge of the evolutionary dynamics of acute leukemias is largely derived from bulk sequencing studies, which have concluded that acute leukemias harbor minimal genetic complexity when compared to other malignant neoplasms 3, 4 . In utero acquisition of an ETV6-RUNX1 translocation has been identified as the most frequent initiating event of acute lymphoblastic leukemia (ALL) 5, 6 , the most common childhood leukemia. However, an ETV6-RUNX1 translocation is insufficient for leukemogenesis 7 ; recent genomic studies have identified deletions of genes required for normal B-cell differentiation 8 that harbor signatures of aberrant RAG recombinase activity as frequent cooperating lesions 9 . In addition, ETV6-RUNX1 ALL cells always harbor somatic single-nucleotide variants (SNVs) 9, 10 . By using single-cell genomics, we determined that most of the deletions occur before the acquisition of SNVs, which result in the outgrowth of co-dominant clonal populations 9 . In addition, analyses of the SNV sequence motifs revealed an important mutagenic role for aberrant cytosine deaminase activity by an APOBEC (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like) protein 9, 10 . As APOBEC proteins mediate innate defense against viral infections 11 , this finding supports the hypothesis that environmental exposure to viruses triggers the transforming mutagenesis 12 . ALL also undergoes clonal evolution between its initial diagnosis and relapse 13, 14 . However, the magnitude of that evolution and the changes in clonal composition between diagnosis and relapse remains unknown.
Several fundamental questions regarding the genesis and treatment response of ETV6-RUNX1 ALL could be more precisely addressed by studying ALL genetics on a population scale. For example, why are there co-dominant clonal populations, especially when some clones harbor known "driver" mutations? What is the total mutation burden across the population of malignant cells, and do the underlying mutational processes change over time? How does this population genetic diversity influence treatment response?
To address these questions, we first used single-cell exome sequencing and error-corrected sequencing to further dissect the intraclonal genetic diversity and the shift in mutational processes that occurred during ETV6-RUNX1 ALL development. These analyses revealed evidence of massive population genetic diversity. Then, after patients began therapy, we examined the evolution of those leukemic clones by exposing samples to standard chemotherapy drugs. Together, our findings enhance our understanding of the development and treatment response of ETV6-RUNX1 ALL at the single-cell level and have significant clinical implications.
Results

Clone-specific "driver" mutations identified by single-cell exome sequencing
To further characterize the genomic diversity of clones previously defined by segregating variants identified in the bulk sample to single cells 10 , we performed single-cell exome sequencing on 3 cells from each clone and on 3 normal cells from the same patient ( Fig. 1A) .
We achieved a mean saturating coverage breadth of 82% of the target exome with 60 million reads, as compared to 95% coverage of the target exome in bulk samples ( Supplementary Fig.   1 ). Using only the single cells, we called mutations by requiring at least 2 cells to have the same base change at the same genomic position. The initial clonal structure had 5 high-frequency clones, with one of the 2 largest clones harboring an E63K KRAS mutation, whereas we could not clearly identify transforming alterations in the other clones ( Fig. 1A) . We then identified a further 10 to 29 mutations per clone ( Fig. 1B) . Using the normal cells as a control, we identified a low false-variant call rate at 7 sites, possibly resulting from clonal mutations acquired in nonmalignant cells, amplification artifacts, or sequencing errors. We then compared the mutagenic base-change pattern of the earlier, higher-frequency mutations that were detected in bulk and were shared between clones to the later, clone-specific changes that were detected only with single-cell exome sequencing. Interestingly, the early mutations were strongly enriched for C-to-T and C-to-G changes with an associated APOBEC motif (T preceding C), whereas the most common later mutations were A-to-G, A-to-C, and C-to-T, with enrichment for G following C. That signature is most consistent with replication errors (Fig. 1C,D) 15 . We also found a KRAS G12S mutation that was confined to a less abundant clone, as well as another clone-specific NRAS G12D variant; both of these mutations were C-to-T changes ( Fig. 1A) .
Because the 3 activating RAS mutations (G12R, G12S, E63K) were acquired in distinct clones and not sequentially, we hypothesized that they occurred over a relatively short time. We then proposed that more oncogenic mutations would be acquired slightly later than the dominant clones, resulting in their being present at even lower frequencies.
Deeper interrogation identifies massive population genetic diversity
To more deeply characterize oncogenic mutations in the bulk sample from the same patient, we performed error-corrected targeted sequencing of 50 mutational hotspots in ALL ( Supplementary Table 1 ). We identified the same 3 RAS mutations (G12R, G12S, E63K) that were detected through bulk and single-cell exome sequencing, along with 2 additional known activating KRAS mutations (G12D, D119N) ( Fig. 2A) [16] [17] [18] [19] , all of which were C-to-T substitutions.
We found no evidence of mutations in the other 37 genes that we examined using a Fisher's exact test cutoff of 0.01. The only benign lesion found in a RAS gene was a G12G mutation that was part of the dinucleotide G12D variant.
To evaluate whether these findings were applicable to a wider range of ETV6-RUNX1 leukemias, we performed error-corrected sequencing on samples from 6 patients with a single RAS mutation identified by bulk sequencing and on 6 samples from patients with no known RAS mutations. We detected no RAS mutations in the latter 6 samples; however, we found a median of 5 activating RAS mutations in the 6 patients for whom a mutation was detected in the bulk samples ( Fig. 2B) . On examining the additional RAS variants more closely, we found the mutations to be clustered at known RAS mutational hotspots, namely KRAS codons 12, 13, 119, and 146 and NRAS codons 12 and 13. There was no clear propensity for variants at specific codons to be subclonal, supporting the assertion that the timing of the acquisition determined whether a mutation became dominant, as opposed to the change in RAS signaling activity due to the specific amino acid change ( Fig. 3C) .
We hypothesized that even more sensitive measurements would identify additional RAS mutations. We performed limited sample dilutions followed by error-corrected sequencing of patient SJETV075, hypothesizing that some RAS mutations that were just below our detection threshold would randomly be present at slightly higher frequencies in the dilute samples. By this approach, we identified 3 additional low-frequency KRAS mutations (G12R, A146T, L19F) for a total of 9 known activating RAS mutations in patient SJETV075. Our examination of all RAS mutations in this cohort revealed that of the 33 mutations identified, 31 were C-to-T or C-to-G changes. The 5 C-to-G changes were enriched for the APOBEC motif, but no similar enrichment was found in the C-to-T mutations, suggesting that they resulted from near-target APOBEC activity or replication-associated mutagenesis. This contrasts with lung cancer, in which approximately 60% of KRAS mutations are G12C or G12V, resulting from C-to-A substitutions 20 .
Together, these observations further support the hypothesis that APOBEC activity and replication-associated mutagenesis are the underlying processes driving the evolution of ETV6-RUNX1 ALL.
We then considered the variables that would result in such a large intra-patient activating RAS mutation burden. In our first model, we proposed that a large population of cells was at risk for rapid RAS-mediated expansion and underwent a widespread mutagenesis process, resulting in the concurrent outgrowth of multiple clones containing mutations conferring similar fitness. In our second model, we proposed that a smaller population was at risk for transformation, with a lower global mutation rate, but that RAS was a mutational hotspot, resulting in the acquisition of multiple RAS mutations during the period of leukemic transformation. If the RAS genes were mutational hotspots for ETV6-RUNX1 ALL, we would expect to find additional benign mutations as passengers of the activating mutations. However, even our more sensitive approach to mutation detection, using both single-cell and error-corrected sequencing, found no additional somatic variants within KRAS, NRAS, or HRAS.
Taken together, these findings support the model in which a massive mutation burden develops within a relatively short time in a population at risk for transformation. To further support this model, we measured the mutation rate in single leukemia cells and used the normal cells from the same sample that had undergone whole-genome amplification in the same microfluidic chip to control for the background mutations and for amplification and sequencing errors. By this approach, we measured a mean of 208 coding mutations per cell that were above the background rate in the normal cells ( Fig. 3A) . Compared to our previous mutation estimation, this approach estimated greater genetic diversity, with each cell harboring a mean of 150 coding variants that were not detected by bulk sequencing or intraclonal exome sequencing ( Fig. 3B) .
Simulation estimates the size and genetic diversity of leukemic populations
Given the large number of mutations per cell, we devised a model to estimate the population size in order to approximate the total genetic diversity across all the clonal populations at the time ALL is diagnosed. To accomplish this, we used those variables that could be estimated from the results of previous studies, along with our current measurements, to simulate ETV6-RUNX1 ALL development. We know that the disease is initiated from a single cell by an ETV6-RUNX1 translocation, as all cells harbor the same breakpoint 5 . Furthermore, each population acquires a mean of 12 deletions 9 . We also know that the disease is initiated in utero and develops over a mean of 4.7 years 21 ; that lymphocyte precursors divide approximately every 11.9 days 22 , whereas primary leukemic cells divide much more frequently; and that replication errors occur in coding regions with a frequency of approximately once in every 300 human cell divisions 24 . From our results, we estimate that each cell had acquired approximately 200 coding SNVs, with many of them arising from APOBEC mutagenesis that occurred in a burst over a short time, randomly resulting in the 16 activating RAS mutations identified in our ETV6-RUNX1 ALL cohort. Cells harboring ETV6-RUNX1, a recurrent deletion, and a RAS mutation have significantly increased rates of replication, resulting in the clinical diagnosis when children reach a total leukemic cell burden of approximately 1 × 10 11 cells (Fig. 4A) .
Using those parameters, we initiated 100 simulations in which the mutation rates resulted in each cell acquiring a mean of 13 deletions and 229 SNVs by a mean of 28 days after a burst of APOBEC mutagenesis (Supplementary Table 2, Fig. 4B ). Defining clones based on cells with the same somatic mutation profile in coding regions, we estimate that there were 330 million clones in total ( Supplementary Table 2 ). However, most clones were created when the overall population size was high, making them rare (Fig. 4C) . The number of high-frequency clones was variable and depended on the time and frequency of RAS mutation acquisition ( Fig. 4D) . We also found evidence that APOBEC mutagenesis and not replication errors caused most of the distinct RAS mutations and that the number of unique RAS mutations varied considerably between simulations (Supplementary Fig. 3 ). Taken together, these simulation results are consistent with our experimental data and support the assertion that there is massive population genetic diversity at the time a patient is diagnosed with ALL.
Massive population diversity drives treatment dynamics in a patient sample
With such high population genetic diversity, we hypothesized that some clones already harbored mutations at diagnosis that altered their susceptibility to treatment. To test that hypothesis, we exposed leukemic cells to 5 standard ALL chemotherapy drugs (mercaptopurine, vincristine, prednisolone, daunorubicin, asparaginase) and used exome sequencing to evaluate the mutational composition after drug exposure. From this initial screen, we identified 537 putative mutations in at least one treatment. We then performed error-corrected sequencing of those sites in triplicate for each treatment to confirm that the mutations were pre-existing.
We detected 224 specific base changes at the same location in more than one sample (Supplemental Table 3 )-approximately 5 times as many mutations as the 41 that we identified in the initial bulk sequencing.
To identify resistant clones, we treated the cells with an increasing dose of each chemotherapy drug and looked for mutations exhibiting a dose-dependent increase in frequency. The control cells treated with no drug or DMSO, as well as the cells treated with the lowest dose of asparaginase, showed an increase in a distinct cluster of mutations. This cluster included the highest-frequency 146V KRAS mutation, along with 2 nonsynonymous TP53 mutations ( Fig. 5 , cluster 7). Interestingly, 2 mutations (FOLH1 R281H and RGPD3 P816C) were strongly selected for in all control and treatment samples but were not detected in the diagnostic sample, suggesting they were selected for by the culture conditions. Treatment with low-dose mercaptopurine or higher doses of asparaginase resulted in reduced expansion of the KRAS A146V clone. This is consistent with the known pharmacokinetics of asparaginase, whereby increasing the dose after target saturation has no effect on cell killing 25 . Treatment with vincristine or dose level 2 of mercaptopurine further decreased the clone(s) in mutation cluster 7 and decreased the frequency of the highest-frequency mutations in cluster 1. Finally, exposure to prednisolone, the highest doses of mercaptopurine, or daunorubicin resulted in the greatest decrease in mutations in clusters 1 and 7, whereas mutations in clusters 2 through 4 increased in frequency as a result of these treatments. Treatment with the highest doses of daunorubicin killed all cellular populations. Taken together, these data show that the underlying genetic diversity when ALL is diagnosed does affect the treatment dynamics.
Discussion
We have presented the results of a combination of error-corrected and single-cell sequencing of ETV6-RUNX1 ALL cells collected at diagnosis in order to further resolve the temporal changes in clonal structures and mutational processes that occur during the development of the disease.
The shift in the relative frequency of different types of cytosine mutation revealed an APOBEC mutagenesis pattern that decreases over time, suggesting that this process is important for disease progression but is not required for persistence or ongoing expansion of leukemic clones. We detected an unexpectedly high population mutation burden, which revealed differences in the treatment response among the clones that arose from the population that had previously undergone APOBEC and replication-mediated mutagenesis. This finding emphasizes the dynamic nature of leukemic evolution, as the relative importance of mutations required for cell survival shifts under distinct selection pressures as patients undergo treatment. We have integrated these findings with previous knowledge to create a new model of ETV6-RUNX1 ALL, which is presented in Figure 6 .
These new details of temporal shifts in the mutational processes of ALL in the period leading up to a patient's clinical presentation highlight how single-cell genomics can be used to trace back the mutational histories of tumors. The decrease in APOBEC-mediated mutagenesis during disease progression removes a major contributor to the global mutation rate in those patients.
This change in the mutation rate may be one reason why ALL patients are cured at such high rates compared to patients with other tumor types in which the source of the mutagenesis, such as a mutation that decreases the fidelity of the DNA repair pathway, does not decrease over time 26 . From our results, it is unclear what effect ongoing exposure to mutagenic chemotherapy agents has on the induction of drug-resistant clones, but the effect could be significant in pediatric patients with ALL, most of whom undergo treatment for 2 to 3 years 27 .
Mutations that are considered driving lesions, such as variants in KRAS or TP53, were not dominant at diagnosis or after undergoing selection during drug treatment, suggesting that combinations of mutations mediate the clinical behaviors of clones. We also observed the rise of clusters of mutations, but it is unclear how many distinct clonal populations those clusters represent. This is an area where higher-resolution studies using single-cell sequencing to determine the co-occurrence patterns of mutations will provide additional insights into drug resistance. The putative high number and differential drug sensitivity of leukemic clones also provide insights into the need for combination therapy to cure children with ALL. Although the sheer genetic diversity of the population presents new challenges for the design of targeted treatment strategies, the presence of massive population genetic diversity in ALL also provides an opportunity to probe those samples to learn why we can already overcome the pre-existent resistance in most patients with ALL. Focusing on specific mutations that are selected for by particular drugs could yield mechanistic insights into drug-specific resistance and provide a new rationale for choosing drug combinations.
In summary, we have provided new insights into the development of ETV6-RUNX1 ALL and its resistance to treatment by studying population genetics. Our findings underscore the importance of studying the mutation burden, size, and mutation rate of the population as a whole, not just the highest-frequency variants detected by standard bulk sequencing, when trying to understand and predict treatment response. Greater genetic diversity has also recently been reported in other premalignant and malignant states 28, 29 , suggesting that the study of cancer population genetics is important for understanding most tumor types.
Together, these studies have revealed new layers of complexity in leukemic evolution that need to be fully understood in order to more effectively eradicate premalignant and malignant ALL cell populations with less treatment-related toxicity, and they have provided a framework for studying intra-tumor evolution in a wide range of malignant neoplasms.
Online Methods
Single-cell exome sequencing and mutation calling
Amplified DNA from patient 4 that had undergone single-cell isolation and whole-genome amplification using the Fluidigm C1 System as previously described 10 MINLEN:30), followed by alignment with BWA using default parameters. Duplicates were marked using Picard (https://broadinstitute.github.io/picard), and local realignment followed by base score recalibration was performed using GATK (https://software.broadinstitute.org/gatk). We then called variants by using GATK and followed this with filtering using the parameter "QD < 2.0 || FS > 60.0 || MQ < 40.0 || HaplotypeScore > 13.0 || MQRankSum < −12.5 || ReadPosRankSum < −8.0". On-target coverage was calculated with Picard HsMetrics; this was repeated after subsampling for an increasing number of reads using custom bash scripts. Custom bash scripts were also used to identify locations that had the same mutation called in more than one cell. Germline SNP locations identified by bulk sequencing were then filtered out, after which locations that were identified in any of the normal single cells were removed.
Error-corrected sequencing
Adapters with unique identifiers were prepared as previously described. Aliquots of 250 or 500 ng of genomic DNA then underwent 30 min of chemical fragmentation and standard library preparation by using the KAPA HyperPlus Kit (Kapa Biosystems) with adapters that contained unique molecular identifiers as described 30 , using 3 μg of adapter per reaction (a 10:1 molar ratio). PCR amplification and hybrid capture were performed as previously described 31 .
Sequencing was performed using MiSeq V2 chemistry, using 2 × 150-bp PE reads. We then trimmed the sequences to 125 bp with Trimmomatic and placed the unique molecular identifiers into the header by using the script tag_to_header.py 30 . Reads were aligned using BWA ALN with standard parameters. We sorted and indexed using Picard then performed consensus calling by using ConsensusMaker.py with parameters -minmem 3, -cutoff 0.8, and --Ncutoff 0.7. Unmapped reads were removed with SAMtools (http://samtools.sourceforge.net/), then local realignment was performed using GATK before creating an mpileup file. Normal and Tumor mpileup files were then compared using VarScan Somatic, with somatic mutations requiring a P-value of less than 10 −4 , as computed using Fisher's exact test by VarScan (http://varscan.sourceforge.net). We also required the germline sample to have fewer than 5 reads and that no more than 90% of variant reads were on the same DNA strand. Variants underwent RefSeq annotation with ANNOVAR.
Estimation of mutation rates
To estimate the mutation rate, we downsampled each of the files to 70 million reads. We then created marked, realigned, and base score-recalibrated BAM files as described above. This was followed by further variant calling and filtering using the GATK filtering parameters detailed above. We then subtracted those sites that were found in the bulk germline sequencing. To subtract the background error rate due to amplification errors, the somatic mosaicism rates in normal cells, and mutation miscalls, we subtracted the mean mutation rate in the 3 normal cells from that of each of the single tumor cells and plotted the distribution of the mutations rates.
Simulation
We designed a computational model to investigate when RAG-mediated deletions and RAS mutations occur, the clonal burden, and the timing of disease onset. The model is initiated with a single cell with an ETV6-RUNX1 translocation that is capable of differentiation and divides every 12 days, defined as cell type 0. At each time point, cells may gain a deletion or, if dividing or if APOBEC mutagenesis is active, an SNV. Type 1 cells are created when type 0 cells gain a specific RAG-mediated deletion, which occurs with probability pRAG_DA. Type 1 cells are considered to have differentiation arrest, but they divide at the same rate as type 0 cells. Type 2 cells are created when type 1 cells have a mutation within RAS, which occurs with probability pMut_IP. Type 2 cells have differentiation arrest as well as increased proliferation, duplicating every day. The number of cells within each cell type with a specific amount of mutations and deletions are tracked. One time point is equivalent to 1 day, and each cell is stochastically sampled.
For each cell of a given type, a random number is generated from 1 to 1/pDel, where pDel is the probability of gaining a deletion. A deletion occurs within cells for which this random number equals 1. A second random number is generated from 1: 1/pRAG_DA for each type 0 cell that acquires a deletion. Any cell in which this second number is 1 contains a deletion that causes it to transform into a type 1 cell. This same process is carried out when calculating the mutational burden as well as the transformation of type 2 cells into type 3 cells.
APOBEC mutagenesis starts on a fixed day, if cell type 3 has not been generated, and continues for 2 days after cell type 3 has formed. Mutations generated from APOBEC are calculated in the same way as previously described, with the exception that every cell within cell types 1 and 2 undergoes APOBEC mutagenesis and the number of mutations caused by APOBEC within a given cell is determined by randomly sampling from 1:Burst. The simulation completes when cell type 3 has reached 1 × 10 11 cells. We estimate the number of cells per clone by the timing of the newly acquired mutation and replication rate, accounting for the branching of cells such that the sum of all cells equals the number of cells of a given type.
Simulations were run using our new R package, which is called RepALL and is available at https://github.com/mjdm/RepALL. We ran the simulation with the following default parameters:
Probability of gaining a RAG-mediated deletion, pRAG: .008
Probability of causing differentiation arrest, given a deletion (Type 0), pRAG_DA: 2e-7
Probability of gaining a mutation due to replication error, pBGMut: 0.003 APOBEC mutagenesis start day: 1290
APOBEC duration after leukemic cell-type initiation: 3 days
Maximum number of APOBEC mutations generated per cell per day, Burst: 75 Probability of gaining a RAS mutation, given a mutation (Type 1), pMut_IP: 16/(3e9*.02) = 2.6e-7
Primary cell culture and drug treatment
Primary samples were from patients that had provided consent in studies approved by the St. Jude IRB. At the time of sample collection, mononuclear cells were isolated using Ficoll-Paque (GE Life Sciences) followed by cryopreservation. One vial of cells from each patient was thawed slowly using the ThawSTAR system (MedCision), and the cells were placed in culture under the conditions previously described 32 . For the limited dilution experiment, 750,000 cells were plated in each well of a 12-well plate and were grown in culture for 3 weeks. For drug treatments, the drugs and 350,000 cells were plated in each well of a 24-well plate. In both experiments, the medium was changed twice weekly by carefully removing half of it and replacing it with fresh medium. The replacement medium included a 2× drug concentration if the cell sample was undergoing chemotherapy exposure. All drugs were purchased from Sigma-Aldrich, and the concentration ranges were based on solubility limits and previously published data 32 . The drugs used were mercaptopurine (500, 250, 125, and 62.5 μg/mL ConsensusMaker.py and 90 μg/mL), vincristine (810, 162, 32.4, and 6.5 μg/mL), daunorubicin (31, 6.2, 1.2, and 0.2 μg/mL), and asparaginase (19, 9.5, 4.8 , and 2.4 μg/mL). Live cells were isolated by using a dead cell removal kit (Miltenyl). DNA was extracted using a DNA Universal Kit (Zymo Research), and libraries were prepared using the HyperPlus Kit (Kapa Biosciences). Exome or custom capture was performed using oligonucleotides and the standard protocol from Integrated DNA Technologies. Quality trimming, alignment, and mutation calling were performed using the pipeline outlined above. 
